{"id":"NCT01857063","sponsor":"Organon and Co","briefTitle":"Study of the Efficacy and Safety of MK-0476 in Japanese Pediatric Participants With Seasonal Allergic Rhinitis (MK-0476-519)","officialTitle":"A Phase III, Double-Blind, Randomized, Placebo-Controlled Cross-over Clinical Trial to Study the Efficacy and Safety of MK-0476 in Japanese Pediatric Subjects With Seasonal Allergic Rhinitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-06-10","primaryCompletion":"2013-09-01","completion":"2013-09-01","firstPosted":"2013-05-20","resultsPosted":"2014-05-26","lastUpdate":"2024-06-17"},"enrollment":220,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Seasonal Allergic Rhinitis"],"interventions":[{"type":"DRUG","name":"Montelukast","otherNames":["montelukast sodium"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Montelukast/Placebo","type":"EXPERIMENTAL"},{"label":"Placebo/Montelukast","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the efficacy and safety of montelukast (MK-0476) in the treatment of Japanese pediatric participants with seasonal allergic rhinitis (SAR). The primary hypothesis of this study is that montelukast is superior to placebo in the treatment of nasal symptoms in SAR.","primaryOutcome":{"measure":"Change From Baseline in Total Nasal Symptom Score (TNSS) Averaged During 3 Hours of Exposure","timeFrame":"Baseline and after 3 hours of pollen exposure on Day 7 of each treatment period","effectByArm":[{"arm":"Montelukast","deltaMin":1.17,"sd":null},{"arm":"Placebo","deltaMin":1.18,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.913"}]},"eligibility":{"minAge":"10 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":3},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["30027002"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":216},"commonTop":["Protein urine present"]}}